The Globe and Mail reports in its Tuesday, April 1, edition that RBC Capital analyst Douglas Miehm has reaffirmed his "outperform" recommendation for Well Health Technologies. The Globe's David Leeder writes in the Eye On Equities column that Mr. Miehm cut his share target back by a loonie to $7.50. Analysts on average target the shares at $8.68. Mr. Miehm says in a note: "Well Health Technologies announced a delay in its annual filings due to an ongoing investigation at Circle Medical. We have long believed that the company should streamline its operations to manage the complexity of its business model and its numerous businesses, which it is attempting to do. The current situation suggests management may have overlooked certain aspects of the complexity. Until we receive further clarity, we include a 50-per-cent contribution of Circle Medical in our valuation ($68-million, or 27 cents/sh) and have also adjusted our valuation to reflect the current market conditions." The Globe reported on Feb. 7, 2024, Dec. 13, 2024, and Jan. 8, 2025, that Mr. Miehm had rated Well Health "outperform." It was then worth $4.01, $6.79 and $7.26.